New hope for kids battling lupus: experimental drug shows promise
NCT ID NCT01649765
Summary
This study tested whether adding the drug belimumab to standard lupus treatment helps children aged 5-17 with active disease. Researchers compared monthly belimumab infusions against placebo infusions in 93 participants over one year, while all continued their regular medications. The goal was to see if belimumab could better control lupus activity and improve quality of life.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Phoenix, Arizona, 85016, United States
-
GSK Investigational Site
Washington D.C., District of Columbia, 20010, United States
-
GSK Investigational Site
Augusta, Georgia, 30912, United States
-
GSK Investigational Site
St Louis, Missouri, 63104, United States
-
GSK Investigational Site
New York, New York, 10032, United States
-
GSK Investigational Site
The Bronx, New York, 10467, United States
-
GSK Investigational Site
Cincinnati, Ohio, 45229, United States
-
GSK Investigational Site
Rosario, 2000, Argentina
-
GSK Investigational Site
Santa Fe, 5400, Argentina
-
GSK Investigational Site
San Luis Potosí City, 78240, Mexico
-
GSK Investigational Site
Lima, Lima 27, Peru
-
GSK Investigational Site
Lima, Lima 5, Peru
-
GSK Investigational Site
Surco, Lima 33, Peru
-
GSK Investigational Site
Saint Petersburg, 194100, Russia
-
GSK Investigational Site
Espluges de Llobregat, 08950, Spain
-
GSK Investigational Site
Madrid, 28034, Spain
-
GSK Investigational Site
Valencia, 46026, Spain
-
GSK Investigational Site
Bristol, BS2 8BJ, United Kingdom
-
GSK Investigational Site
Liverpool, L12 2AP, United Kingdom
-
GSK Investigational Site
London, NW1 2PG, United Kingdom
-
GSK Investigational Site
London, WC1N 3JH, United Kingdom
Conditions
Explore the condition pages connected to this study.